Summary
The purpose of this study is to determine whether HGF serum concentration might be raised in vivo by administering nadroparin given with prophylactic purpose to gynecological patients.
Key Facts
Lead Sponsor
Enrollment
Start Date
Study Type
Official Title
Conditions
Eligibility
Age Range
Sex
Inclusion Criteria: * ≥ 18 years * ECOG PS ≤ 1 * Neutrophils ≥ 1500 l -1, platelets ≥ 150,000 l -1, creatinine 0.6 to 1.2 mg dl -1, total bilirubin ≤ 1 mg dL -1, AST ≤ 35 U l-1, ALT ≤ 45 U l-1 For patients in the study group: high-moderate risk of deep vein thrombosis (for the administration of LMWH for 30 days after surgery) under general anesthesia\> 30 minutes, laparoscopy + at least one risk factor (age\> 40 years, obesity, varicose veins, previous episode of deep vein thrombosis and / or pulmonary thromboembolism, thrombophilia, malignancy, prolonged immobility, congestive heart failure) Exclusion Criteria: * severe liver and renal disease * diabetes * hyperlipidemia * marked osteoporosis * HIV infection * ongoing treatment with: immunosuppressive therapies, contraceptives, lipid-lowering drugs, NSAIDs, antiplatelet drugs, recent acute inflammatory or infectious (\<3 weeks) * a history of allergies, * drug possible confounding, caffeine, tobacco, ethanol (must not have been hired in the last 24 hours prior to sampling) * high risk of bleeding: peptic ulcer, history of hemorrhagic stroke, or bleeding disorders, severe hypertension, cerebral aneurysms, arteriovenous malformations, brain metastases